Tyrosine Kinase Inhibitor Imatinib Mesylate Alters DMBA-Induced Early Onco/Suppressor Gene Expression with Tissue-Specificity in Mice

Figure 1

Experimental design. Six- to eight-week-old (n=36) conventionally raised NMRI inbred mice were divided randomly into three sets: the negative control group was i.p. treated with the vehicle (corn oil) (1st set, n=12), the positive control group (2nd set, n=12) was treated i.p. with a 20 mg/kg body weight dose DMBA (7,12-dimethylbenz[a]anthracene), and the experimental group (3rd set, n=12) was treated i.p. with 10 mg/kg imatinib mesylate and 20 mg/kg DMBA. Animals were autopsied 24 hours after treatment, and organs were dissected and stored for further analysis.